CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

venipuncture in peripheral veinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2232 Serological Assay or IgG for SARS-CoV-2 Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Effect of SARS-CoV-2 Infection on Platelet Aggregation and Other Coagulation Parameters

This is a mechanistic, observational, prospective, case and control study, to compare platelet aggregation, analyzed by Multiplate-ADP, in hospitalized patients diagnosed with COVID-19 versus healthy controls. Thus will be included 50 patients who present with respiratory symptoms within 72 hours of hospitalization and confirmation of the diagnosis of COVID-19 by laboratory method (RT -PCR and / or positive serology for SARS-CoV-2 - COVID group); this group will be compared to 50 healthy individuals (asymptomatic and with negative SARS-CoV-2 serology), matched by sex and age to the previous group.

NCT04447131 COVID-19 SARS-CoV-2 Other: venipuncture in peripheral vein

Primary Outcomes

Description: Compare platelet aggregation analyzed by Multiplate-ADP in hospitalized patients diagnosed with COVID-19 versus healthy controls.

Measure: Platelet aggregation analyzed by Multiplate-ADP

Time: at inclusion

Secondary Outcomes

Description: Compare platelet aggregation by Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus healthy controls.

Measure: Platelet aggregation by Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus healthy controls.

Time: at inclusion

Description: Compare the levels of the reticulated platelet fraction in patients hospitalized for COVID-19 versus healthy controls.

Measure: Reticulated platelet fraction in patients hospitalized for COVID-19 versus healthy controls.

Time: at inclusion

Description: Compare platelet aggregation by Multiplate-ADP, Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus patients hospitalized for respiratory symptoms but negative for Influenza and COVID-19 research.

Measure: Platelet aggregation for COVID-19 versus patients hospitalized for respiratory symptoms but negative for Influenza and COVID-19 research.

Time: at inclusion

Description: Compare the levels of the reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for respiratory symptoms but negative for influenza or COVID-19 research.

Measure: Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for respiratory symptoms but negative for influenza or COVID-19 research.

Time: at inclusion

Description: Compare platelet aggregation by Multiplate-ADP, Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.

Measure: Platelet aggregation in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.

Time: at inclusion

Description: Compare the levels of the reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.

Measure: Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.

Time: at inclusion

Description: Compare the levels of platelet aggregation (by Multiplate ADP, ASPI and TRAP) in patients with or without the composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization Compare the levels of platelet aggregation (by Multiplate ADP, ASPI and TRAP) in patients with or without the composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization

Measure: Platelete aggreggation versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization

Time: at inclusion

Description: Compare the levels of the reticulated platelet fraction in patients with or without the composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization;

Measure: Reticulated platelet fraction versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization

Time: at inclusion

Description: Compare the levels of platelet aggregation (by Multiplate ADP, ASPI and TRAP) with the time (days) of total hospitalization and in the ICU;

Measure: Platelet aggregation versus time (days) of total hospitalization and in the ICU

Time: at inclusion

Description: Correlate the levels of the reticulated platelet fraction with the time (days) of total hospitalization and in the ICU;

Measure: Reticulated platelet fraction versus time (days) of total hospitalization and in the ICU

Time: at inclusion

Description: Correlate the levels of platelet aggregation (by Multiplate ADP, ASPI and TRAP) and the fraction of reticulated platelets with maximum score obtained on the WHO ordinal scale of outcomes for COVID-19 within 28 (± 3 days) of inclusion:

Measure: Platelet aggregation versus WHO ordinal scale of outcomes for COVID-19

Time: within 28 (± 3 days) of inclusion

No related HPO nodes (Using clinical trials)